Please use this identifier to cite or link to this item:
|Title:||Cellular and organismal toxicity of the anti-cancer small molecule, tolfenamic acid: a pre-clinical evaluation.||Authors:||Sankpal, Umesh T.
Lee, Chris M.
Connelly, Sarah F.
Zawia, Nasser H.
Lichtenberger, Lenard M.
|Issue Date:||2013||Publisher:||Karger||Abstract:||Background/Aims: The small molecule, Tolfenamic acid (TA) has shown anti-cancer activity in pre-clinical models and is currently in Phase I clinical trials at MD Anderson Cancer Center Orlando. Since specificity and toxicity are major concerns for investigational agents, we tested the effect of TA on specific targets, and assessed the cellular and organismal toxicity representing pre‐clinical studies in cancer. Methods: Panc1, L3.6pl, and MiaPaCa-2 (pancreatic cancer), hTERT-HPNE(normal), and differentiated/un-differentiated SH-SY5Y (neuroblastoma) cells were treated with increasing concentrations of TA. Cell viability and effect on specific molecular targets, Sp1 and survivin were determined. Athymic nude mice were treated with vehicle or TA (50mg/kg, 3times/week for 6 weeks) and alterations in the growth pattern, hematocrit, and histopathology of gut, liver, and stomach were monitored. Results: TA treatment decreased cell proliferation and inhibited the expression of Sp1 and survivin in cancer cells while only subtle response was observed in normal (hTERT-HPNE) and differentiated SH-SY5Y cells. Mice studies revealed no effect on body weight and hematocrit. Furthermore, TA regimen did not cause signs of internal-bleeding or damage to vital tissues in mice. Conclusion: These results demonstrate that TA selectively inhibits malignant cell growth acting on specific targets and its chronic treatment did not cause apparent toxicity in nude mice||Description:||LEE,Chris: Connelly,Sarah: Kayaleh,Omer: Eslin,Don:||URI:||http://hdl.handle.net/20.500.11889/2699|
|Appears in Collections:||Fulltext Publications|
Show full item record
checked on Nov 17, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.